Endocrine Society Applauds Eli Lilly’s Efforts to Lower Insulin Costs

Monthly price caps should be available to everyone who depends on insulin

The Endocrine Society commends Eli Lilly and Company for taking steps to reduce insulin prices and make insulin affordable for more people with diabetes.

Eli Lilly’s announcement to cut insulin prices by 70% and extend the $35 per month insulin cap to people with private insurance is a positive step towards making insulin affordable for the more than 7 million Americans that rely on the medication.

“Lilly’s move to apply a $35/month cap for people with private insurance will be a significant improvement for adults and children with diabetes who use Lilly’s products,” says Endocrine Society Chief Medical Officer Robert Lash, MD. “We encourage all insulin manufacturers to join in the effort to reduce out-of-pocket costs for people who need insulin.”

The Endocrine Society has championed measures to improve insulin access for years. Last year, we were pleased that a $35/month cap on insulin for people with Medicare was included in the Inflation Reduction Act and implemented this January 1. The Endocrine Society continues to call on Congress to pass an insulin price cap for all people with private insurance.

More than 7 million people nationwide rely on insulin to manage their diabetes. According to the U.S. Center for Disease Control and Prevention, 37.3 million people nationwide — about 11% of Americans — have diabetes.

While insulin was discovered more than 100 years ago, the price of insulin nearly tripled between 2002 and 2013, and the trend upward has continued over the past decade. In 2021 alone, nearly one in five American adults with diabetes — about 1.3 million people — rationed their insulin to save money, according to a study.

The Society will continue to work to improve insulin access for all who need it.

“Our patients who rely on insulin have waited long enough. The time to act is now,” Lash adds.

You may also like

  • Endocrine Society Journals Earn Higher Impact Factors for 2021 

    The Endocrine Society’s Journals experienced sizeable Impact Factor gains, led by Endocrine Reviews, according to Clarivate’s recently released annual Journal Citation Report (JCR) for 2021.  A highly regarded metric used to measure the success of scholarly journals, the 2021 Impact Factor is calculated by tracking how many times articles that a journal published in 2019…

  • Hammer Wins Inaugural Endocrine Images Art Competition

    Gary Hammer, MD, PhD, Millie Schembechler professor of Adrenal Cancer at the University of Michigan in Ann Arbor, Mich., won the Endocrine Society’s Endocrine Images Art Competition, a contest celebrating the beauty of endocrine science. Entries were judged based on aesthetic value and significance to endocrine research. Hammer’s image of the adrenal gland took the top…

Find more in